Ebglyss (lebrikizumab-lbkz) / Roche, Almirall, Eli Lilly - LARVOL DELTA

Real-World Effectiveness of Lebrikizumab in Patients With Head-Neck Atopic Dermatitis: A Multicenter Study With Focus on Flare Occurrence. (PubMed, Int J Dermatol) - "Lebrikizumab demonstrated rapid and sustained effectiveness in patients with HND, with marked improvements in disease severity, pruritus, and quality of life. Head-neck flares were relatively uncommon and generally manageable with topical therapies."

Clinical • Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Lebrikizumab Showed Sustained Efficacy and Safety Through 5 Years in Patients with Moderate-to-Severe Atopic Dermatitis: Results from the ADlong Long-Term Extension Trial (EADV 2026) - No abstract available

Clinical • Late-breaking abstract • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Lebrikizumab is effective in Patients with Atopic Hand and Foot Dermatitis: 16-Week Results from the Randomized, Double-Blind, Placebo-Controlled ADTouch Trial (EADV 2026) - No abstract available

Clinical • Late-breaking abstract • Dermatitis • Dermatology • Immunology

Lebrikizumab in Atopic Dermatitis: Associations of Patient Characteristics and Treatment History with Clinical Outcomes. (PubMed, Dermatitis) - "Lebrikizumab demonstrated favorable real-world effectiveness and safety in adults with moderate-to-severe AD after 16 weeks of treatment, with clinical and patient-reported improvements maintained through week 24."

Clinical data • Journal • Atopic Dermatitis • CNS Disorders • Conjunctivitis • Dermatitis • Dermatology • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • Sleep Disorder

Comparative disproportionality of adverse events across four type 2 inflammation-targeting biologics for atopic dermatitis: a FAERS analysis of dupilumab, tralokinumab, lebrikizumab, and nemolizumab (EADV 2026) - No abstract available

Adverse events • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Lebrikizumab achieves rapid facial clearance in severe atopic dermatitis refractory to Dupilumab and JAK inhibitors (EADV 2026) - No abstract available

Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Comparative Efficacy of Dupilumab, Tralokinumab, and Lebrikizumab on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A Frequentist Network Meta-Analysis (EADV 2026) - No abstract available

Patient reported outcomes • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Bimekizumab as an Effective Treatment in Darier Disease: Clinical Outcomes of a Single-Center Retrospective Analysis of Patients Treated with Biologics. (PubMed, Dermatol Ther (Heidelb)) - "In summary, these real-world data indicate that bimekizumab may be a beneficial and relatively safe treatment option in DD."

Clinical data • Journal • Retrospective data • Dermatology • Immunology • Inflammation • IL17A

Real-world experiences with Lebrikizumab in patients with severe Atopic Dermatitis (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Lebrikizumab as an effective therapeutic alternative in a frail patient with refractory prurigo nodularis (EADV 2026) - No abstract available

Clinical • Immunology • Prurigo Nodularis

Lebrikizumab Provides Clinically Meaningful Response in Face and Hands in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: ADhope 1 Study (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Lebrikizumab Safety in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis: Results from the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study ADorable-1 through Week 16. (EADV 2026) - No abstract available

Clinical • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Preliminary real-world patient-reported outcomes and mHealth engagement with lebrikizumab in moderate-to-severe atopic dermatitis: a multicenter ePROM study using the NAVETA platform (EADV 2026) - No abstract available

Clinical • Patient reported outcomes • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Lebrikizumab Shows Efficacy in Patients with Moderate-to-Severe Atopic Dermatitis, Including Patients with Predominantly Moderate Disease (ADhope 1) (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Impact of Head and Neck Involvement on Clinical Response to Lebrikizumab in Atopic Dermatitis: A Real-World Cohort Study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Lebrikizumab Achieved High Levels of Absolute EASI Optimal Response in Patients with Moderate-to-Severe Atopic Dermatitis for Up to 3 Years (ADvocate 1 & 2 to ADjoin) (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Head and Neck Clearance with Lebrikizumab in Atopic Dermatitis: A Real-World Cohort Study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Longitudinal laboratory profile of patients with moderate-to-severe atopic dermatitis treated with lebrikizumab or tralokinumab in real-world clinical practice (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy and safety of lebrikizumab in the treatment of atopic dermatitis in the head-and-neck area complicated by eczema herpeticum: a case report. (EADV 2026) - No abstract available

Case report • Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Baseline Disease Burden and High Treatment Persistence at Six Months with Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: A Real-World Analysis from a Canadian Patient Support Program (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Impact of Lebrikizumab on Dermatology-Related Emergency Department Visits in Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

When context matters: successful management of severe atopic dermatitis during lactation with lebrikizumab (EADV 2026) - No abstract available

Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Lebrikizumab as a treatment for moderate-to-severe atopic dermatitis: a structured literature review (EADV 2026) - No abstract available

Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Severe chronic hand eczema successfully treated with lebrikizumab in a patient with moderate-to-severe atopic dermatitis (EADV 2026) - No abstract available

Clinical • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Lebrikizumab Improves Itch and Sleep in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis: Results from the Phase 3 ADorable-1 Study (EADV 2026) - No abstract available

Clinical • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics